Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transducin-like enhancer of split 2 (TLE2) is a transcriptional corepressor protein that belongs to the Groucho/TLE family of WD repeat domain-containing proteins[3]. It interacts with various DNA-binding transcription factors to mediate transcriptional repression, functioning primarily in the nucleus. TLE2 is involved in the negative regulation of gene expression and canonical Wnt signaling pathways[3]. In the context of Kaposi's sarcoma-associated herpesvirus (KSHV) infection, TLE2 forms a nuclear complex with the viral replication and transcription activator (RTA), repressing RTA-driven autoactivation and viral gene transactivation, thus contributing to viral latency maintenance[1][2][3]. TLE2 exerts its corepressor function via specialized domains (Q, SP, and WDR), and its activity can antagonize transcriptional programs essential for cell fate and disease processes including cancer and viral infection[1][2][3].
Not applicable; no drugs reported
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transducin-like enhancer of split 2 (TLE2).